BYSI News and Press, BeyondSpring Inc. From 09/08/20

BeyondSpring (NASDAQ: BYSI )   +9.5%  in premarket as the FDA and China’s Center for Drug Evaluation  designates the company's Plinabulin as a Breakthrough Therapy for the treatment of chemotherapy-induced neutropenia (CIN). More news on: BeyondSpring...

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - - Designation Based on PROTECTIVE-2 Phas...

Image source: The Motley Fool. BeyondSpring Inc.   (NASDAQ: BYSI) Q2 2020 Earnings Call Sep 3, 2020 , 8:00 a.m. ET Operator Continue reading

BeyondSpring Inc. (BYSI) Q2 2020 Earnings Conference Call September 3, 2020 8:00 A.M. ET Company Participants Scott Eckstein - Vice President at KCSA Strategic Communications Lan Huang - Co-Founder, Chairman and Chief Executive Officer Ramon Mohanlal - Executive Vice President, R...

BeyondSpring (NASDAQ: BYSI ) : Q2 GAAP EPS of -$0.46  beats by $0.11 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone- - Completed PROTECTIVE-2 Phase 3 Enrollment and On Track to Report Final R...

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-q...

Our analysis concludes the share prices of oncology-related companies are down, on average, 25% from peaking the third week of June 2020. With the exception of Agenus Inc. ( AGEN ), that appears to be trading higher on anticipation its vaccine adjuvant will be used in 2 or more of the eventual...

NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has ap...

Our analysis concludes BeyondSpring Inc. ( BYSI ) offers investors exponential gain potential if BYSI's first NDA submitted in China and anticipated NDA submission in the United States are approved. This is because BYSI's product, Plinabulin, has estimated peak revenue potential in the billion...